DMS PHARMACEUTICAL GROUP INC

DMS PHARMACEUTICAL GROUP INC has $458,079 in federal contract obligations across 59 award records in the ingested USAspending contract dataset. Figures are derived from procurement award type codes A, B, C, and D only.

Quick answer

DMS PHARMACEUTICAL GROUP INC has $458,079 in ingested federal contract obligations across 59 award records in this contractor profile.

Contractor Snapshot

Total obligations$458,079
Award records59
Entity codePX72BSBQTKJ3
Data updatedMay 7, 2026
Top relationshipDepartment of Defense
Top category325411 - MEDICINAL AND BOTANICAL MANUFACTURING

Source: USAspending.gov. Last updated from ingested federal spending data: May 7, 2026.

Market Analysis

DMS PHARMACEUTICAL GROUP INC has $458,079 across 59 ingested award records, with the analysis below generated only from visible tables on this page.

Trend Direction

DMS PHARMACEUTICAL GROUP INC increased from FY2024 to FY2025, moving from $112,799 to $343,931 in the ingested records.

  • Latest: $343,931
  • Previous: $112,799

Concentration

Department of Defense accounts for 100.0% of DMS PHARMACEUTICAL GROUP INC's visible obligations in this slice, which is the first concentration signal to review before treating the market as broad or fragmented.

  • Top relationship: Department of Defense
  • Top value: $458,079

Buyer And Category Mix

325411 - MEDICINAL AND BOTANICAL MANUFACTURING is the largest visible secondary category at $417,668. Use this alongside the relationship table to separate one-off award activity from repeat market exposure.

  • Largest secondary category: 325411 - MEDICINAL AND BOTANICAL MANUFACTURING
  • Category value: $417,668

Recent Award Signal

The latest displayed award is SPE2D325F082G from FY2025 with $81,735 in obligations. Recent rows help identify whether the profile is still active in current procurement data.

  • Award date: Not listed
Source caveats
  • USAspending records can be revised after initial publication.
  • Negative obligations and deobligations may affect totals in narrow slices.

Spending by Fiscal Year

FY202552 awards$343,931
FY20245 awards$112,799
FY20231 awards$13
FY20211 awards$1,337

Top Agencies

Department of Defense59 awards$458,079

Top NAICS Codes

325411 - MEDICINAL AND BOTANICAL MANUFACTURING42 awards$417,668
325412 - PHARMACEUTICAL PREPARATION MANUFACTURING15 awards$32,155
424210 - DRUGS AND DRUGGISTS' SUNDRIES MERCHANT WHOLESALERS2 awards$8,256

Recent Awards

AwardRecipientFiscal yearObligationsDate
SPE2D325F082GDMS PHARMACEUTICAL GROUP INC2025$81,735Not available
SPE2D324F209XDMS PHARMACEUTICAL GROUP INC2024$36,638Not available
SPE2D324F184LDMS PHARMACEUTICAL GROUP INC2024$32,501Not available
SPE2D325F144SDMS PHARMACEUTICAL GROUP INC2025$32,110Not available
SPE2D024F0135DMS PHARMACEUTICAL GROUP INC2024$27,774Not available
SPE2D325F8769DMS PHARMACEUTICAL GROUP INC2025$26,856Not available
SPE2D325F7908DMS PHARMACEUTICAL GROUP INC2025$26,856Not available
SPE2D325F0008DMS PHARMACEUTICAL GROUP INC2025$26,592Not available
SPE2D225F0001DMS PHARMACEUTICAL GROUP INC2025$25,224Not available
SPE2D325F289QDMS PHARMACEUTICAL GROUP INC2025$23,706Not available
Citation facts

DMS PHARMACEUTICAL GROUP INC has $458,079 in ingested federal contract obligations across 59 award records in this contractor profile.

Source
USAspending.gov procurement award records
Data updated
May 7, 2026
Canonical URL
https://www.govspending.us/contractor/dms-pharmaceutical-group-inc-px72bsbqtkj3

Federal Contract Questions

How much federal contract spending is associated with DMS PHARMACEUTICAL GROUP INC?

DMS PHARMACEUTICAL GROUP INC has $458,079 in ingested contract obligations across 59 award records.

Which relationships matter most for DMS PHARMACEUTICAL GROUP INC?

Department of Defense is the largest listed relationship in this profile at $458,079.

Which industries or buyers are most visible?

325411 - MEDICINAL AND BOTANICAL MANUFACTURING is the largest listed secondary category at $417,668.

Source: USAspending.gov. Last updated from ingested federal spending data: May 7, 2026.

Methodology